Analyst Price Target is $50.38
▲ +99.66% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Rocket Pharmaceuticals in the last 3 months. The average price target is $50.38, with a high forecast of $65.00 and a low forecast of $35.00. The average price target represents a 99.66% upside from the last price of $25.23.
Current Consensus is
The current consensus among 9 investment analysts is to buy stock in Rocket Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. The company is headquartered in Cranbury, New Jersey.